PDE5A and myocardial infarction: Although there are still safety issues concerning PDE5 inhibitor use in patients with coronary artery disease, recent studies have shown that the use of PDE5 inhibitors, even in a post-MI cohort, reduced mortality and HF hospitalizations8.